Oxford Metrics Returns to Revenue Growth and Meets EBIT Expectations in FY25

Oxford Metrics FY25 trading update: revenue growth returns and profits on track

Oxford Metrics (LSE: OMG) has served up a neat FY25 trading update: year-on-year revenue growth is back, Adjusted EBIT is in line with expectations, and cash remains chunky after a year of buybacks, dividends and acquisitions. The Group has balanced a tough backdrop in US academia with strength in smart manufacturing, setting up a steadier base for FY26.

If you like businesses that quietly compound and return cash while investing for growth, this is worth a closer look.

Headlines at a glance

• Revenue growth returned year-on-year, with full-year revenue expected to be broadly in line with market expectations.
• Adjusted EBIT in line with consensus.
• Vicon resilient despite US academic funding headwinds, with better momentum elsewhere.
• Smart manufacturing (IVS and Sempre) delivered strong performance with both organic and inorganic growth.
• Year-end cash of £37.0 million after £5.4 million on acquisitions, £4.2 million in dividends, and £8.3 million on buybacks.
• Preliminary results due in early December 2025.

Key figures and market consensus

Metric	FY25 Guidance/Outcome	Consensus (per RNS)
Revenue	Broadly in line	£46.2m
Adjusted EBIT	In line	£2.3m
Year-end cash	£37.0m	Not applicable
Capital returns and M&A	Buybacks £8.3m, dividend £4.2m, acquisitions £5.4m	Not applicable

Adjusted EBIT is earnings before interest and tax, adjusted for certain non-cash or one-off items as defined by the company. On consensus numbers, this implies an Adjusted EBIT margin of around 5%.

Revenue broadly in line and profitability steady

The line that stands out is simple but important: year-on-year revenue growth returned. While the update does not disclose the actual revenue figure, the Group says it expects to be broadly in line with market expectations of £46.2 million, and Adjusted EBIT in line with £2.3 million.

That combination suggests a steady top line and disciplined cost control through a year that included notable investment and capital returns. It is not flashy, but it is reassuring.

Vicon holds its ground despite US academic funding headwinds

Vicon, the motion capture arm serving healthcare, entertainment and engineering, faced a tougher backdrop in the US this year due to academic funding changes. That is a well-telegraphed headwind from the interim results and not one Oxford Metrics can control. The encouraging bit is that Vicon still delivered a “resilient” performance, helped by improved activity in other geographies and end-markets.

The read-across: the demand for motion measurement in entertainment and healthcare appears intact, but the regional mix is shifting. Investors will want more colour in December on order intake, regional split and any timing effects that could unwind positively in FY26.

Smart manufacturing is doing the heavy lifting

The star of the update is smart manufacturing. Both Industrial Vision Systems (IVS) and Sempre performed strongly, with “healthy organic and inorganic growth” driven by better management and product delivery execution. That is classic Oxford Metrics: build and buy niche technology businesses, then improve them.

Organic growth refers to expansion from the existing operations, while inorganic growth comes from acquisitions. The fact both contributed suggests momentum is broad-based rather than a one-off acquisition sugar hit. Given the end-markets – medical devices, pharmaceuticals, aerospace and precision engineering – this strength also speaks to quality of demand.

Cash balance shows firepower despite returns and deals

Oxford Metrics ended the year with £37.0 million in cash, after spending £5.4 million on acquisitions, £4.2 million on dividends and £8.3 million on share buybacks. That is a lot of moving parts, yet the balance sheet remains healthy. It gives management room to keep investing while continuing capital returns if they see value.

The mix of dividends and buybacks suggests a balanced approach. Buybacks of £8.3 million hint at management confidence in the intrinsic value of the shares, while the dividend keeps a steady income stream for holders.

CEO framing: innovation and diversification front and centre

CEO Imogen O’Connor calls FY25 “a year of strong strategic progress” with new product launches and a push into diversified, high-value niches aligned to market trends. That aligns with the operational picture: resilience at Vicon, growth engines in manufacturing, and continued investment for the long term.

What’s missing at this stage are the precise growth rates, order book details and margin bridge. Those should come with the prelims in early December.

Why this update matters for investors

• Return to revenue growth is a key signal. After a wobble in US academic funding, the Group has stabilised and grown through geographic and market diversification.
• Consensus delivered. Hitting the revenue and Adjusted EBIT range matters for credibility, especially while integrating acquisitions and launching new products.
• Smart manufacturing momentum. IVS and Sempre look like the near-term growth levers, potentially smoothing Vicon cyclicality.
• Capital allocation discipline. Cash of £37.0 million after dividends, buybacks and acquisitions keeps optionality open.

On the flip side, the implied Adjusted EBIT margin of around 5% is modest. For the equity story to really hum, investors will look for operating leverage – better margins as revenue scales – particularly from the higher-growth manufacturing division.

Key watch-outs for the December prelims

• Segmental detail: revenue and profit split between Vicon, IVS and Sempre, including regional trends and end-market mix.
• Order intake and pipeline: any catch-up from deferred US academic spending, and strength in non-US geographies.
• Margin bridge: drivers of Adjusted EBIT, including gross margin, operating costs and the impact of acquisitions.
• Cash deployment: updated stance on further buybacks, dividend policy and M&A appetite given the £37.0 million cash balance.
• New product traction: measurable uptake from recent launches and how that feeds FY26 growth.

My take: steady execution with upside if margins improve

This is a solid, confidence-building update. Revenue growth is back, profitability is where the market expected, and the balance sheet is robust after a year of both investment and returns. The strategic split is working as intended: smart manufacturing is carrying growth while Vicon navigates a temporary funding headwind in US academia.

The investment case from here hinges on two things: sustained growth in IVS and Sempre, and evidence that the Group can push that circa 5% Adjusted EBIT margin higher. If they can deliver both, FY26 could look meaningfully better. For now, it is a reassuring hold for long-term investors and one to revisit after the December results when the detail lands.